India, April 6 -- Semaglutide, a GLP-1 receptor agonist commonly used to treat type 2 diabetes and support weight loss, is now being rolled out by England's National Health Service (NHS) as a ...
Thousands of NHS patients who could benefit from the weight-loss jab Mounjaro are missing out due to funding issues. Less than half of commissioning bodies across England have started prescribing the ...
People who are not obese but overweight and at risk of serious cardiovascular events will be eligible for weekly jabs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results